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Abstract
Introduction:  Allergic  rhinitis  is  considered  the  most  prevalent  respiratory  disease  in  Brazil  and
worldwide, with  great  impact  on  quality  of  life,  affecting  social  life,  sleep,  and  also  performance
at school  and  at  work.
Objective:  To  compare  the  efﬁcacy  and  safety  of  two  formulations  containing  mometasone
furoate in  the  treatment  of  mild,  moderate,  or  severe  persistent  allergic  rhinitis  after  four
weeks of  treatment.
Methods:  Phase  III,  randomized,  non-inferiority,  national,  open  study  comparing  mometasone
furoate  in  two  presentations  (control  drug  and  investigational  drug).  The  primary  endpoint  was
the percentage  of  patients  with  reduction  of  at  least  0.55  in  nasal  index  score  (NIS)  after  four
weeks of  treatment.  Secondary  outcomes  included  total  nasal  index  score  score  after  four  and
12 weeks  of  treatment;  individual  scores  for  symptoms  of  nasal  obstruction,  rhinorrhea,  sneez-
ing, and  nasal  pruritus;  as  well  as  score  for  pruritus,  lacrimation,  and  ocular  redness  after  four
and 12  weeks  of  treatment.  The  study  was  registered  at  clinicaltrials.gov  with  the  reference
number NCT01372865. Please cite this article as: Antila MA, Castro FM, Sano F, Machado A, Fernandes F, Rosário Filho NA, et al. Mometasone furoate in the
reatment of mild, moderate, or severe persistent allergic rhinitis: a non-inferiority study (PUMA). Braz J Otorhinolaryngol. 2016;82:580--8.
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Results:  The  efﬁcacy  primary  analysis  demonstrated  non-inferiority  of  the  investigational  drug
in relation  to  the  control  drug,  since  the  upper  limit  of  the  conﬁdence  interval  (CI)  of  95%  for
the difference  between  the  success  rates  after  four  weeks  of  treatment  (12.6%)  was  below  the
non-inferiority  margin  provided  during  the  determination  of  the  sample  size  (13.7%).  Adverse
events were  infrequent  and  with  mild  intensity  in  most  cases.
Conclusion:  The  efﬁcacy  and  safety  of  investigational  drug  in  the  treatment  of  persistent  aller-
gic rhinitis  were  similar  to  the  reference  product,  demonstrating  its  non-inferiority.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/).
PALAVRAS-CHAVE
Rinite  alérgica
persistente;
Furoato  de
mometasona;
Não  inferioridade
Furoato  de  mometasona  no  tratamento  de  rinite  alérgica  persistente  leve,  moderada
ou  grave:  estudo  de  não  inferioridade  (PUMA)
Resumo
Introduc¸ão: A  rinite  alérgica  é  considerada  a  doenc¸a  respiratória  mais  prevalente  no  Brasil  e
em todo  o  mundo,  com  grande  impacto  na  qualidade  de  vida;  além  de,  afetar  a  vida  social,  o
sono e  também  o  desempenho  na  escola  e  no  trabalho.
Objetivo:  Comparar  a  eﬁcácia  e  seguranc¸a de  duas  formulac¸ões  contendo  furoato  de  mometa-
sona no  tratamento  da  rinite  alérgica  persistente  leve,  moderada  ou  grave  por  um  período  de
quatro semanas.
Método:  Trata-se  de  um  estudo  nacional  aberto  de  fase  III,  randomizado,  de  não  inferioridade
de comparac¸ão  do  furoato  de  mometasona  em  duas  apresentac¸ões  (medicac¸ão  de  controle  e
fármaco  sob  investigac¸ão).  O  ponto  ﬁnal  primário  foi  o  percentual  de  pacientes  com  reduc¸ão
mínima de  0,55  no  escore  de  índice  nasal  (EIN)  após  quatro  semanas  de  tratamento.  Os  desfechos
secundários  foram:  escore  NIS  total  após  4  e  12  semanas  de  tratamento;  escores  individuais
para sintomas  de  obstruc¸ão  nasal,  rinorréia,  espirros  e  prurido  nasal,  bem  como  escores  para
prurido, lacrimejamento  e  hiperemia  conjuntival  após  4  e  12  semanas  de  tratamento.  O  estudo
foi registrado  em  clinicaltrials.gov  com  o  número  de  referência  NCT01372865.
Resultados:  A  análise  de  eﬁcácia  primária  demonstrou  não  inferioridade  do  fármaco  sob
investigac¸ão em  relac¸ão  à  medicac¸ão  de  controle,  visto  que  o  limite  superior  do  intervalo  de
conﬁanc¸a (IC)  de  95%  para  a  diferenc¸a  entre  os  percentuais  de  sucesso  após  quatro  semanas  de
tratamento  (12,6%)  situava-se  abaixo  da  margem  de  não  inferioridade  proporcionada  durante  a
determinac¸ão do  tamanho  da  amostra  (13,7%).  Eventos  adversos  foram  pouco  frequentes  e  de
leve intensidade  na  maioria  dos  casos.
Conclusão:  A  eﬁcácia  e  a  seguranc¸a de  um  fármaco  experimental  no  tratamento  da  rinite
alérgica persistente  foram  similares  às  do  produto  de  referência,  o  que  demonstrou  sua  não
inferioridade.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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Allergic  rhinitis  is  an  allergic  disease  characterized  by
chronic  inﬂammation  of  the  mucous  membranes  of  the
respiratory  tract.  Its  main  symptoms  are  nasal  congestion,
sneezing,  anterior  and  posterior  rhinorrhea,  nasal  pruri-
tus,  ocular  and  palatal  pruritus,  conjunctival  injection,  and
lacrimation.1,2
Considered  the  most  prevalent  respiratory  disease  in
Brazil  and  worldwide,  recent  estimates  indicate  that
approximately  500  million  people  suffer  from  allergic
rhinitis.1,3 In  the  United  States,  it  is  believed  that  10--30%  of
adults  and  40%  of  children  are  affected  by  allergic  rhinitis.4
In  Brazil,  it  is  estimated  that  the  average  prevalence
O
t
rn  adolescents  and  schoolchildren  is  29.6%  and  25.7%,
espectively.3,5
Clinical  manifestations  of  allergic  rhinitis  occur  after  the
nteraction  of  a  speciﬁc  allergen  and  the  immune  system
f  previously  sensitized  individual.  Immediate  hypersensi-
ivity  is  a fast  reaction  with  participation  of  IgE  and  mast
ells  followed  by  inﬂammation.6 Other  allergic  diseases
ay  be  associated  with  rhinitis,  such  as  asthma  and  atopic
ermatitis.7
In  1999,  the  Allergic  Rhinitis  and  its  Impact  on  Asthma
ARIA)  workgroup,1,8 in  collaboration  with  World  Health
rganization  (WHO),  provided  a  base  of  evidence  to  facili-
ate  the  diagnosis  and  treatment  of  the  disease.  The  group
ecommended  that  allergic  rhinitis  be  classiﬁed  according
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o  the  duration  (intermittent  or  persistent)  and  intensity  of
ymptoms  (mild  or  moderate/severe).9
Although  benign,  allergic  rhinitis  has  a  signiﬁcant  impact
n  quality  of  life,  affecting  social  life,  sleep,  as  well  as
chool  and  labor  performance.1,8 The  main  goal  of  treat-
ent  is  to  prevent  or  relieve  symptoms  with  maximum  safety
nd  efﬁcacy.  Ideally,  the  treatment  of  allergic  rhinitis  should
im  primarily  the  action  on  cells  and  inﬂammatory  medi-
tors,  thereby  minimizing  the  symptoms  of  the  disease.
everal  classes  of  drugs  are  used  in  the  treatment,  such
s  oral  or  topical  antihistamines,  intranasal  decongestants,
eukotriene  receptor  antagonists,  and  topical  intranasal  cor-
icosteroids.  The  latter  are  recognized  as  the  ﬁrst-choice
rugs  in  anti-inﬂammatory  treatment  of  moderate  to  severe
llergic  diseases.1,8,10,11
The  mechanism  of  action  of  corticosteroids  includes
hemical  mediators  and  cells  involved  in  the  allergic  inﬂam-
atory  process  that  establishes  the  rhinitis.  Intranasal
ormulations  have  the  advantage  of  local  administration,
ith  faster  onset  of  action  compared  to  systemic  thera-
ies.  Moreover,  it  has  been  reported  that  corticosteroids
ay  help  control  comorbidities  of  rhinitis,  such  as  allergic
onjunctivitis  and  asthma.10,12
Mometasone  furoate  is  a  synthetic  glucocorticoids  for
opical  intranasal  use,13 which  inhibits  the  formation,
elease,  and  activity  of  endogenous  chemical  mediators,
lso  limiting  cellular  phase  of  allergic  inﬂammation.  Its
ntranasal  application  controls  the  initial  and  late  allergic
esponse.14
Given  the  previously  demonstrated  efﬁcacy  of  mometa-
one  furoate  in  the  treatment  of  allergic  rhinitis,  the  present
tudy  was  designed  to  test  the  non-inferiority  of  the  new
ormulation  compared  to  the  control  product.  The  primary
bjective  was  to  compare  the  efﬁcacy  of  both  drugs  in  the
reatment  of  persistent  allergic  rhinitis  after  four  weeks.
ethods
his  was  a  phase  III,  randomized,  non-inferiority,  national,
ulticenter  (seven  centers),  open  study,  aiming  to  compare
he  new  experimental  formulation  of  mometasone  furoate
Eurofarma)  to  the  control  drug  (Nasonex®,  Schering-Plough
harmaceuticals  Ltd.)  administered  in  total  daily  dose  of
00  g  (two  sprays  of  100  g  in  each  nostril  once  daily).
The  study  was  approved  by  the  research  ethics  com-
ittees  of  the  institutions  involved  under  the  number  CE
o.  106/2012  (issued  on  May  17th,  2012)  and  all  study  par-
icipants  signed  an  informed  consent  (IC).  In  addition,  it
as  sponsored  by  Eurofarma  Laboratórios  S.A.  Patients  with
ild,  moderate,  or  severe  persistent  allergic  rhinitis  were
ncluded,  according  to  the  ARIA  criteria,1,8 with  total  nasal
ndex  score  (NIS)  value  ≥4  at  the  screening  visit  and  on  at
east  four  of  the  seven  days  preceding  this  visit.  Patients
lso  were  required  to  be  >12  years  of  age,  with  symptoms
f  allergic  rhinitis  for  at  least  two  years  (conﬁrmed  by  a
ositive  skin  test  to  at  least  one  relevant  aero-allergen  con-
ucted  over  the  past  90  days),  and  also  have  prescribed  use
f  nasal  corticosteroid.  Furthermore,  patients  were  required
o  undergo  a  washout  period  of  14  ±  5  days  between  the
creening  (SV)  and  the  randomization  visit  (RV)  without  use
f  any  nasal,  oral,  or  parenteral  corticosteroids  (including
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ntihistamines;  oral  or  topical  nasal  vasoconstrictor;  and
orticosteroids  in  any  route  of  administration  --  except  cuta-
eous).  If  the  research  subject  required  other  medication,
e/she  was  excluded  from  the  study  to  continue  treatment
ccording  to  local  practices.
The  study  was  conducted  in  open-label  setting,  with
o  blinding  of  interventions.  Blinding  prevents  possible
iases  in  clinical  trials;  however,  sometimes  it  cannot  be
pplied.  This  study  was  open  because  the  drugs  studied  have
ery  different  appearances,  which  would  make  the  blind-
ng  infeasible.  Nevertheless,  the  symptoms  diary  and  the
dditional  tests  prevented  the  occurrence  of  any  bias  in  the
valuation  of  the  researchers.  Thus,  the  fact  that  this  study
as  open  does  not  impact  the  quality  of  data  collected.
Patients  with  severe  comorbidities  (according  to  the
nvestigator  criteria);  moderate  to  severe  persistent
sthma;  history  of  respiratory  tract  infection  within  30  days
rior  to  the  study  entry;  structural  changes  causing  nasal
bstruction  (excessively  deviated  septum,  nasal  polyps,  or
ny  type  of  nasal  malformation);  as  well  as  patients  in  need
f  other  medicines  to  treat  allergic  rhinitis;  pregnant  or
actating  patients;  active  smokers  in  the  last  three  months
rior  to  enrollment  in  the  study;  and  those  who  participated
n  another  clinical  study  in  the  past  12  months  were  not
ncluded  in  the  study.
After  stratiﬁcation  according  to  the  research  center  and
o  the  intensity  of  allergic  rhinitis  (mild  versus  moderate  or
evere),  patients  were  randomized  in  a  1:1  ratio  to  receive
ne  of  the  study  treatments.  The  research  subjects  were
andomized  centrally,  according  to  a list  created  by  an  appli-
ation  to  generate  random  sequences.  The  randomization
nd  allocation  of  treatment  was  conducted  electronically
hrough  an  electronic  case  report  ﬁle  (CRF).  Treatment
as  automatically  registered  in  the  appropriate  ﬁeld  on
he  medical  records  of  the  study.  All  randomized  patients
eceived  at  least  one  dose  of  study  medication  and  received
o  different  drug  than  that  he  or  she  was  randomized  to
eceive.  The  follow-up  period  for  each  patient  was  14  weeks
nd  the  scheduled  duration  of  active  treatment  was
2  weeks.
After  RV,  patients  were  assessed  in  four  visits  (V1,  V2,  V3,
nd  FV).  During  the  study,  patients  completed  a  diary  con-
aining  information  about  the  symptoms  of  allergic  rhinitis,
asal  obstruction,  rhinorrhea,  sneezing  and  nasal  pruritus,
s  well  as  the  score  for  pruritus,  lacrimation,  and  ocular  red-
ess  after  four  and  12  weeks  of  treatment,  drug  adherence,
nd  use  of  rescue  medications.  At  each  visit  the  symptoms
ere  rated  on  a  scale  from  0  to  3,  which  was  summed  to
onstitute  the  endpoint  of  NIS  in  the  study  period.
The  primary  endpoint  was  the  proportion  of  patients  with
 reduction  of  at  least  0.55  points  in  the  NIS  score  after  four
eeks  of  treatment,  compared  with  baseline,  using  data
ecorded  in  the  diary.  This  threshold  was  deﬁned  based  on
he  study  conducted  by  Barnes  et  al.,15 in  which  it  was  deter-
ined  that  a  reduction  of  0.55  points  in  another  combined
core,  the  total  nasal  symptom  score  (TNSS),  is  the  minimal
linically  important  difference  (MCID)  and,  therefore,  can
e  considered  clinically  signiﬁcant  for  patients  treated  with
ntranasal  corticosteroids.  Similar  to  the  NIS,  the  TNSS  is  the
um  of  scores  for  a  group  of  symptoms,  each  measured  on
n  ordinal  scale  of  0,  1,  2,  or  3,  representing  no  symptoms,
ild,  moderate,  or  severe  symptoms,  respectively.  Instead
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of  3,  the  TNSS  combines  the  score  of  four  symptoms  (nasal
run,  blockage,  itchiness,  and  sneeze),  so  it  can  range  from
0  to  12.  As  there  was  no  such  data  on  the  MCID  for  the  NIS,
and  in  both  scores,  symptoms  are  individually  scored  from
0  to  3  and  contribute  equally  to  the  total  sum  (no  different
weight  is  attributed  to  different  symptoms),  it  was  assumed
that  if  a  0.55  reduction  is  clinically  signiﬁcant  in  a  scale  from
0  to  12  it  would  also  be  in  a  0  to  9  scale.  If  a  proportional
extrapolation  of  the  threshold  was  done,  a  reduction  of  0.55
in  the  0  to  12  point  scale  (TNSS)  would  represent  a  reduction
of  0.41  in  the  0  to  9  NIS  scale.  Thus,  an  approach  using  the
threshold  of  0.55  point  in  the  NIS  to  deﬁne  clinical  beneﬁt
can  be  considered  conservative.
Secondary  outcomes  included  total  NIS  score  after  four
and  12  weeks  of  treatment;  assessment  of  individual  and
overall  scores  for  symptoms  of  nasal  obstruction,  rhinorrhea,
and  sneezing  using  NIS  score;  and  assessment  of  scores  of
nasal  pruritus  and  pruritus,  lacrimation,  and  ocular  redness
performed  by  the  investigator  at  each  visit  to  the  research
center;  as  well  as  the  frequency  of  adverse  events.
Statistical  methods
To  calculate  NIS  at  baseline,  the  mean  values  of  valid
measures  of  the  score  for  each  patient  in  the  seven  days  pre-
ceding  the  RV  were  used.  To  calculate  NIS  after  four  weeks,
the  mean  values  of  the  fourth  week  of  treatment  were  used,
considering  the  data  recorded  in  the  diary.
In  the  present  study,  the  main  efﬁcacy  measure  was
the  NIS,  a  combined  score  calculated  by  the  sum  of
individual  scores  of  three  nasal  symptoms  (nasal  conges-
tion/obstruction,  runny  nose,  and  sneezing).  Each  symptom
was  individually  graded  from  0  (no  symptom)  to  3  (severe
symptoms),  and  the  total  NIS  can  range  from  0  to  9.  Although
the  TNSS  score  is  more  frequently  used,  the  NIS  is  a  valid
scale  and  has  been  used  in  several  studies  to  assess  the  efﬁ-
cacy  of  intranasal  corticosteroids  in  seasonal  and  perennial
rhinitis.16--19
For  the  per  protocol  (PP)  population,  the  results  obtained
for  nasal  congestion  (obstruction),  runny  nose,  and  sneez-
ing  are  shown  as  individual  symptoms  and  as  a  combined
score  (NIS).  In  addition  to  these  three  symptoms  that  con-
stitute  the  NIS,  patients  had  to  grade  in  their  diaries  the
other  two  symptoms  (one:  nasal  pruritus,  and  two:  pruri-
tus,  lacrimation,  and  ocular  redness),  which  were  analyzed
individually.
No  imputation  of  missing  data  was  taken.  Continuous
variables  were  summarized  by  means  of  variation  (minimum
and  maximum),  mean,  standard  deviation  (SD),  median,  and
interquartile  range  (IQR,  25th  percentile,  and  75th  per-
centile).  Categorical  variables  were  described  by  means  of
relative  frequencies.
When  comparing  both  groups,  parametric  or  non-
parametric  methods  were  used,  according  to  the
distribution  pattern  of  the  outcome  variables.  The
Kolmogorov--Smirnov  test  with  Lilliefors  correction  was
used  to  assess  the  pattern  of  distribution  of  the  outcome
variables  in  the  sample.
Continuous  variables  with  normal  distribution  were  com-
pared  using  t-tests,  while  non-normally  distributed  variables
were  compared  using  the  Mann--Whitney  non-parametric
s
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est.  Categorical  variables  were  compared  using  the  chi-
quared  or  Fisher’s  exact  test,  according  to  the  number  of
ndividuals.  For  the  multivariate  analysis  of  the  proportions
f  patients  with  reduction  of  ≥0.55  in  NIS  total  score  over
ime  in  both  groups,  the  ANOVA  test  with  repeated  measures
as  used,  with  Greenhouse--Geisser  correction.
Two-tailed  levels  of  signiﬁcance  of  5%  were  used  as
ndicative  of  statistical  differences  between  groups.  For
eclaration  of  non-inferiority  of  the  investigational  drug
ompared  to  the  control  drug,  the  upper  limit  of  the  95%
I  for  the  difference  between  the  proportions  of  patients  in
oth  groups  with  reduction  of  ≥0.55  in  the  total  NIS  score
control  drug  minus  investigational  drug)  after  four  weeks
f  treatment  should  be  up  to  13.7%  in  absolute  values.  If
on-inferiority  was  demonstrated,  a  superiority  test  would
e  performed,  with  a  two-tailed  level  of  5%  as  indicative  of
igniﬁcant  difference  between  groups.
Analyses  were  performed  using  Microsoft  Excel  soft-
are  (Microsoft  Ofﬁce  2007)  for  descriptive  analyses,  and
 statistical  software  (v.  2.13.1)  and  MedCalc  (v.  11.3.3.0,
ariakerke,  Belgium),  for  inferential  analyzes.
ample  size  determination
ased  on  the  literature,  the  determination  of  sample  size
n  the  non-inferiority  design  of  the  study  considered  the  NIS
core  after  four  weeks  of  equal  treatment  in  both  groups.
onsidering  a  one-tailed  alpha  error  of  2.5%  and  a statistical
ower  of  80%  for  the  study  to  ﬁnd  the  maximum  difference  of
3.7%  or  less  between  the  control  and  investigational  arms
limit  for  non-inferiority),  164  patients  would  be  included  in
ach  arm  of  the  study.  Assuming  that  there  would  be  a  loss
f  follow  up  of  approximately  15%,  the  study  would  include
93  patients  in  each  arm,  i.e.,  a  total  of  386  patients.
A  non-inferiority  margin  (M)  of  13.7%  was  determined.
he  determination  of  the  non-inferiority  margin  was  based
n  the  maximum  acceptable  difference  between  experimen-
al  and  control  groups,  as  judged  by  the  specialists,  in  order
o  assure  for  the  experimental  group  the  retention  of  a  min-
mum  of  the  beneﬁcial  effect  of  treatment  in  relation  to
lacebo  or  absence  of  medication.  In  addition,  the  non-
nferiority  margin  chosen  for  this  study  is  in  accordance  with
he  European  Medicines  Agency’s  guidelines  and  other  pub-
ications  that  recommend  the  use  of  margins  between  10%
nd  20%,  depending  on  the  therapeutic  ﬁeld.
esults
tudy  population
etween  May  and  September  2012,  568  subjects  with  mild,
oderate,  or  severe  persistent  allergic  rhinitis,  classiﬁed
ccording  to  the  ARIA  criteria,  were  included  in  the  study,
nd  387  of  them  were  randomized  to  receive  one  of  the  study
rugs.  The  reasons  for  randomization  failure  are  shown  in
able  1.All  subjects  enrolled  received  at  least  one  dose  of  the
tudy  medication  and  none  had  received  a  different  drug
han  the  one  established.  Fig.  1  shows  the  patients  ﬂow  in
he  study  according  to  the  treatment  groups.
584  
Table  1  Reasons  for  randomization  failure.
Reason  n  (%)
Eligibility  failure  105  (58.2)
Loss to  follow-up  4  (2.2)
Consent  withdrawal  9  (4.8)
Lack of  adherence  to  protocol  6  (3.3)
Use of  medications  not  allowed  in  the  study  11  (6.1)
End of  position  in  one  of  the  strata  in  the  study  46  (25.4)
568 screened patients
181 selection failure
387 randomized at RV
191 patients randomized to
receive the investigational drug
196 patients randomized to
receive the control drug
1 elegibility
failure
195 entered ITT population
175 entered PP population171 entered PP population
191 entered ITT population
Figure  1  Flow  of  patients  in  the  study  (ITT,  intent  to  treat
population;  PP,  per-protocol  population;  RV,  randomization
visit).
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Table  2  Demographic  characteristics  of  the  ITT  and  PP  subgroup
Characteristic  ITT  population  (n  =  38
Investigational
drug
(n  =  191)
Con
(n =
Gender,  n  (%)
Women  119  (62.30)  117
Men 72  (37.70)  78  
Age, years  (mean  ±  SD)  27.74  ±  12.51  31.
Range 12.19--70.38  12.
Median (IQR)  25.12
(17.60--34.39)
28.
(18
Ethnicity,  n  (%)
White  112  (58.64)  120
Mixed 32  (16.75)  33  
African-American  42  (21.99)  37  
Asian 5  (2.62)  5  (
BMI, km/m2 (mean  ±  SD) 24.96  ±  5.39  25.
Range 15.27--44.31 15.
Median (IQR) 24.13
(20.76--28.41)
24.
(21
History  of  smoking;  n  (%)
Non-smokers  177  (92.67)  181
Ex-smokersa 14  (7.33)  14  
SD, standard deviation; BMI, body mass index; NIS, nasal index scor
per-protocol population.
a Stopped smoking three months prior to study entry.Antila  MA  et  al.
All  of  the  387  randomized  patients  received  at  least  one
ose  of  the  study  medication  and  entered  the  safety  sample.
ne  randomized  subject  violated  an  eligibility  criterion  and
he  study  was  discontinued  at  the  time  the  violation  became
nown.  Thus,  this  subject  was  excluded  from  the  intention-
o-treat  (ITT)  and  per  protocol  (PP)  subgroups.
Forty  of  the  386  subjects  in  the  ITT  population  did  not
nter  the  PP  population  due  to:  lack  of  data  for  evalua-
ion  of  the  primary  endpoint  (n  =  23);  use  of  medication  not
llowed  in  the  study  (n  =  10);  or  use  of  higher  doses  of  rescue
edication  between  week  one  and  week  four  of  the  study
n  = 7).  The  ITT  population  was  therefore  composed  of  386
atients,  the  PP  population  of  346  patients,  and  the  safety
opulation  of  386  patients.
Seventy-seven  of  386  randomized  patients  were  pre-
aturely  discontinued  from  the  study  due  to  concomitant
isease  (n  = 4),  lack  of  adherence  to  protocol  or  treatment
n  = 19),  loss  to  follow  up  (n  =  24),  consent  withdrawal  (n  =  3),
oxicity  or  adverse  events  (n  =  2)  or  use  of  medications  not
llowed  in  the  protocol  during  the  study  (n  =  24).
The  demographic  characteristics  of  patients  are  pre-
ented  in  Table  2.
fﬁcacy  endpointymptoms  of  allergic  rhinitis  were  evaluated  by  NIS  score,
hich  included  the  evaluation  of  individual  symptoms  such
s  nasal  congestion/obstruction,  runny  nose,  and  sneezing.
n  addition  to  these  symptoms,  patients  had  to  grade  in  their
s.
6)  PP  Population  (n  =  346)
trol  drug
 195)
Investigational
drug
(n  =  171)
Control  drug
(n  =  175)
 (60.00)  107  (62.57)  108  (61.71)
(40.00)  64  (37.43)  67  (38.29)
04  ±  14.41  28.04  ±  12.81  31.15  ±  14.42
01--67.54  12.19--70.38  12.00--67.54
79
.68--41.35)
25.39
(17.69--34.94)
28.79
(19.01--41.40)
 (61.54)  99  (57.89)  109  (62.29)
(16.92)  28  (16.37)  27  (15.43)
(18.97)  39  (22.81)  34  (19.43)
2.56)  5  (2.92)  5  (2.86)
02  ±  5.07  24.65  ±  5.36  25.03  ±  4.84
27--45.92  15.27--44.31  15.27--39.81
61
.90--27.29)
23.72
(20.55--28.13)
24.64
(21.95--27.36)
 (92.82)  158  (92.40)  162  (92.57)
(7.18)  13  (7.60)  13  (7.43)
e; IQR, interquartile range; ITT, intent to treat population; PP,
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diaries  the  other  two  symptoms:  nasal  pruritus;  and  pruritus,
lacrimation,  and  ocular  redness;  which  were  analyzed  indi-
vidually.  There  was  no  signiﬁcant  difference  between  the
groups,  except  for  nasal  obstruction:  according  to  the  data
recorded  in  the  diary,  the  score  for  nasal  obstruction  at  base-
line  was  signiﬁcantly  higher  in  the  investigational  arm  than
in  the  control  arm  (Fig.  2).
The  efﬁcacy  primary  analysis  was  performed  by  evaluat-
ing  the  non-inferiority  of  the  investigational  drug  compared
to  the  control  drug.  Table  3  shows  the  comparison  between
the  success  rates  in  the  two  treatment  groups  in  PP  pop-
ulation.  It  can  be  observed  that  76.6%  of  patients  in  the
investigational  arm  and  80%  in  the  control  arm  had  a  reduc-
tion  of  at  least  0.55  in  NIS  score  after  four  weeks  of
treatment  and  that  there  was  no  statistically  signiﬁcant  dif-
ference  between  groups  (p  =  0.586).
The  95%  CI  for  the  difference  between  the  success  rates
(investigational  drug  and  control  drug)  after  four  weeks  of
treatment,  obtained  by  proportions  equality  test  with  conti-
nuity  correction,  was  −5.87  to  12.65.  Fig.  3  shows  the  results
graphically,  with  the  upper  limit  of  the  CI  (12.7%)  below  the
non-inferiority  margin  (M  =  13.7%).  Thus,  the  non-inferiority
of  the  investigational  drug  compared  to  the  control  drug  was
demonstrated.
As  observed  in  the  PP  population,  there  was  a  signiﬁcant
effect  of  treatment  time  on  the  values  of  NIS  (p  <  0.0001)
and  no  signiﬁcant  difference  between  groups  (p  =  0.624)  in
the  ITT  population.  The  values  of  NIS  score  in  the  investi-
gational  arm  were  5.61  ±  1.52;  3.34  ±  2.06;  and  2.34  ±  1.91
before  treatment  and  after  four  and  12  weeks  of  treatment,
w
i
t
t
Table  3  Comparison  of  the  proportions  of  patients  with  a  reducti
in both  groups,  PP  population  (n  =  346).
Reduction  of  at  least  0.55  in  NIS  score  after  4  weeks  of  treatment  
Yes  
No 
PP, per-protocol population; NIS, nasal index score.
a Mann--Whitney test.n =  346).
espectively.  The  group  treated  with  the  control  drug
howed  a  NIS  score  of  5.51  ±  1.36;  3.24  ±  2.07;  and
.34  ±  1.91  before  treatment  and  after  four  and  12  weeks
f  treatment,  respectively  (Fig.  4).
se  of  rescue  medication
fter  the  beginning  of  the  treatment,  54.3%  of  the  patients
ho  received  the  control  drug  and  45.71%  of  those  receiv-ng  the  investigational  drug  used  ebastine  during  the  study
reatment.  There  was  no  signiﬁcant  difference  between  the
reatment  arms.
on  of  at  least  0.55  in  NIS  score  after  four  weeks  of  treatment
Investigational  drug,  n  (%)  Control  drug,  n  (%)  pa
(n  =  171)  (n  =  175)
131  (76.6)  140  (80.0)  0.586
40  (23.4)  35  (20.0)
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in  this  score  can  be  considered  clinically  signiﬁcant.  Theigure  4  Total  NIS  score  over  time  based  on  patient  diary,  PP
opulation  (n  =  308).
afety  results
able  4  shows  the  level  of  serum  cortisol  in  the  beginning
f  the  study  (SV)  and  after  four  weeks  of  treatment  (FV)  in
oth  treatment  groups,  considering  the  safety  population.
he  comparison  of  medians  showed  no  signiﬁcant  difference
etween  groups  in  the  beginning  or  in  the  end  of  treatment.
In  the  safety  population,  235  patients  presented  non-
erious  adverse  events  during  the  study.  In  the  control  group,
19  of  191  patients  (62.30%)  had  an  adverse  event,  and  in  the
nvestigational  arm,  116  of  196  patients  (59.2%)  presented
n  adverse  event  (p  =  0.530).  With  the  exception  of  epistaxis
nd  myalgia,  more  frequent  in  the  control  arm,  and  abnor-
al  electrocardiogram,  more  frequent  in  the  investigational
rm,  there  was  no  signiﬁcant  difference  between  groups  in
he  frequency  of  adverse  events.  The  most  frequent  adverse
vents  in  both  groups  were  back  pain,  cough,  dysmenorrhea,
eadache,  and  nasopharyngitis.
There  was  a  report  of  a  single  serious  adverse  event  dur-
ng  the  study,  classiﬁed  as  perianal  abscess,  which  occurred
n  the  control  arm  and  was  unrelated  to  the  study  medica-
ion.  There  were  no  reports  of  death  during  the  study.
p
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Table  4  Level  of  serum  cortisol  in  SV  and  FV  (mg/dL)  in  the  safe
Cortisol  Investigational  drug  
SV,  g/dL  n  =  191  
Range 0.29--40.11  
Mean ±  SD  11.97  ±  7.27  
Median (IQR)  10.30  (6.70--15.40)  
FV, g/dL  n  =  168  
Range 2.90--37.87  
Mean ±  SD  13.64  ±  7.05  
Median (IQR)  12.10  (8.84--17.01)  
SD, standard deviation; IQR, interquartile range; SV, screening visit; FV
a Mann--Whitney test.Antila  MA  et  al.
iscussion
llergic  rhinitis  is  an  inﬂammatory  disease  of  the  nasal
ucosa  with  high  prevalence  worldwide  --  which  has  been
ncreasing  in  recent  years,  enhancing  the  interest  of  differ-
nt  medical  ﬁelds  and  of  public  health  in  the  subject.
In  persistent  rhinitis,  nasal  obstruction  is  often  the  pre-
ominant  symptom.  In  these  cases,  corticosteroids  are  the
rugs  of  ﬁrst  choice  and  may  or  may  not  be  associated
ith  antihistamine/decongestant,20 constituting  the  only
rug  class  that  promotes  signiﬁcant  improvement  of  all
ymptoms,  such  as  pruritus,  sneezing,  rhinorrhea,  and  nasal
ongestion.8
The  update  of  the  ARIA  clinical  recommendations1
ollowing  the  approach  taken  by  GRADE  (grading  of  rec-
mmendations  assessment,  development,  and  evaluation)
ndicates  the  use  of  intranasal  corticosteroids  for  the  treat-
ent  of  allergic  rhinitis  in  adults  and  also  suggests  their  use
n  children.  This  decision  indicates  the  high  value  of  the  efﬁ-
acy  of  intranasal  corticosteroids  and  the  low  value  of  their
ossible  adverse  events.8
Mometasone  furoate  is  a potent  corticosteroid,  as
emonstrated  by  receptor  afﬁnity,  and  it  has  a  lower
ioavailability  compared  to  other  formulations.21 High
ower  and  low  availability  confer  efﬁcacy  and  safety  to
ometasone  furoate.22
The  efﬁcacy  primary  analysis,  performed  considering  the
rimary  endpoint  in  the  PP  population,  demonstrated  the
on-inferiority  of  the  investigational  drug  in  relation  to  the
ontrol  drug  for  the  treatment  of  persistent  allergic  rhini-
is  of  any  intensity,  since  the  upper  limit  of  the  95%  CI  for
he  difference  between  the  success  rates  after  four  weeks
f  treatment  (12.7%)  was  below  the  non-inferiority  margin
eﬁned  (13.7%).
Most  studies  on  intranasal  corticosteroids  in  patients  with
ild  to  moderate  persistent  allergic  rhinitis  identiﬁed  in  the
iterature  evaluate  nasal  symptoms  using  the  TNSS  scale,
hich  includes  nasal  obstruction,  sneezing,  rhinorrhea,  and
ruritus.  These  symptoms  are  individually  ranked  from  0
no  symptoms)  to  3  (severe  symptoms)  and  the  total  score
anges,  therefore,  from  0  to  12.  A  decrease  of  at  least  0.55resent  study  used  a scale  which  includes  only  nasal  obstruc-
ion,  rhinorrhea,  and  sneezing  as  symptoms,  also  ranked
rom  0  (no  symptoms)  to  3  (severe  symptoms),  ranging  from
ty  population  (n  =  387).
Control  drug  pa
n  =  196
2.26--38.51
11.91  ±  6.52
10.44  (7.34--15.20)  0.736
n  =  171
1.0--39.48
13.17  ±  6.60
11.90  (8.70--15.91)  0.747
, ﬁnal visit.
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1Mometasone  furoate  in  the  treatment  of  mild,  moderate,  or
0  to  9.  Thus,  the  use  of  the  value  0.55  in  the  present  study
can  be  considered  conservative.
Most  individuals  with  allergic  rhinitis  have  ocular  symp-
toms  -- about  two-thirds  of  asthma  patients  have  symptoms
of  allergic  rhinoconjunctivitis.23 However,  the  diagnosis  of
allergic  conjunctivitis  is  undervalued  by  physicians.  Ocu-
lar  symptoms  associated  with  allergic  rhinitis  are  caused
by  the  direct  contact  of  the  allergen  with  the  conjuncti-
val  mucosa,  and  nasal-ocular  reﬂexes  would  constitute  an
indirect  pathway,  depending  on  histamine  release,  since  it
is  blocked  with  topical  intranasal  antihistamine.  Evidence-
based  clinical  research  shows  that  intranasal  corticosteroids
promote  relief  of  nasal  and  ocular  symptoms,  but  the
mechanism  how  intranasal  corticosteroids  improve  ocular
symptoms  remains  unknown.  ARIA  guidelines  recommend
the  use  of  intranasal  corticosteroids  for  treatment  of  allergic
rhinoconjunctivitis.8,24
Regarding  security,  few  numerical  differences  were
observed  between  groups  in  some  of  the  analyses,  and  it
seems  that  there  is  not  a  pattern  that  allows  asserting
which  of  the  treatment  is  less  toxic.  Some  adverse  events
were  recorded  in  only  one  of  the  study  groups.  For  adverse
events  that  were  recorded  in  both  groups  and  could  be
compared  to  the  frequency,  no  statistically  signiﬁcant  differ-
ences  between  treatments  were  found,  except  for  epistaxis
and  myalgia  -- more  frequent  in  the  control  arm  --  and
abnormal  electrocardiogram  -- more  common  in  the  inves-
tigational  arm.  However,  it  is  important  to  note  that  the
adverse  events  were  not  related  to  the  drugs  assessed  in  this
study.  The  main  adverse  events  of  intranasal  corticosteroids
are  rare,  even  when  the  use  is  extended.22
Measurement  of  plasma  cortisol  in  the  morning  is  sensi-
tive  enough  to  determine  systemic  activity  of  corticosteroids
on  the  adrenal  gland,  although  other  tests  might  be
used  with  greater  accuracy  for  this  purpose.21 A  recent
review,  including  more  than  20  studies  and  6000  patients
treated  with  mometasone  furoate,  found  no  effect  on
the  hypothalamic-pituitary  axis.25 Furthermore,  the  use  of
mometasone  furoate  for  12  months  did  not  cause  atrophy
and  metaplasia  of  the  nasal  mucosa,  representing  further
evidence  of  its  safety,  even  with  prolonged  use.26
Although  frequently  seen  as  a  trivial,  ﬂeeting,  or  minor
illness,  allergic  rhinitis  can  signiﬁcantly  impair  the  quality
of  life  of  patients,  affecting  school  learning  and  workplace
productivity.27,28 This  is  because  symptoms  such  as  sneezing
in  bursts,  nasal  pruritus,  and  nasal  congestion  can  lead  to
fatigue,  difﬁculty  in  concentrating  and  learning,  headache
and,  in  some  cases,  sleep  disorders  such  as  apnea.29--31
Conclusion
Mometasone  furoate  is  a  safe  and  effective  drug  for
the  treatment  of  persistent  allergic  rhinitis.  The  study
demonstrated  non-inferiority  in  efﬁcacy  and  safety  of  inves-
tigational  drug  compared  to  the  control  drug,  validating  the
proposed  development  as  an  option  for  the  treatment  of
patients  with  mild,  moderate,  or  severe  persistent  allergic
rhinitis.Conﬂicts of interest
The  authors  declare  no  conﬂicts  of  interest.
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